Keynote Speakers
Meet the ECP 2026 Keynote Speakers
The ECP Scientific Committee has selected the following world-renowned experts to share their research with the pathology community:
Giuseppe Curigliano, Italy
Keynote Details
Speaker Details
KNL-01 | Sunday, 13 September
11:45 - 12:30
Title yet to be announced
Giuseppe Curigliano, MD PhD,
is the director of the Early Drug Development Division and holds the co-chair for Experimental Therapeutics Program at the European Institute of Oncology, a comprehensive cancer center in Milano, Italy. He is professor of Medical Oncology in the Department of Oncology and Hemato-Oncology at the University of Milano.
In ESMO he served as Chair the ESMO Nomination Committee (2017-2019) and as Chair of the ESMO Clinical Practice Guideline Committee (2019-2023). He was one of the founding member and served as scientific Co-Chair of the “ESMO Breast Cancer Congress”. He contributed to launch the ESMO Living Guidelines and to the recognition of the Fellow of ESMO (FESMO). He organized and participated to many professional and educational congresses for oncologists all over the world.
Professor Curigliano was identified as Clarivate™ world’s most influential researchers (the highly cited researchers) in 2022, 2023 and 2024. He has authored more than 900 papers in peer-reviewed journals (h-index 100) and many book chapters. He served as editorial board member for international journals in oncology (European Journal of Oncology, Journal of Clinical Oncology, Annals of Oncology). He is a panel member of several international breast cancer consensus conferences and has served as a chair or steering committee member for numerous national and international conferences. He trained, mentored and sponsored dozens of medical oncologists from Latin America, Africa, Asia and Italy.
Professor Curigliano was awarded with the first ESO Umberto Veronesi Award (2017) and with the Fellowship of the European Academy of Cancer Sciences in Paris (2017). He served as Editor in Chief of ESMO Open from 2022 to 2025. He is ESMO President elect.
Cecilia Halle, Sweden
Keynote Details
Speaker Details
KNL-02 | Monday, 14 September
11:45 - 12:30
Title yet to be announced
Cecilia Halle is Director-General and Head of the Department for Healthcare and Pharmaceuticals at the Ministry of Health and Social Affairs. She has extensive experience in governmental governance as well as in national and international policy work in the fields of healthcare and medical preparedness. Cecilia represents Sweden on the Board of the European Health Emergency Preparedness and Response Authority (HERA), serves as Sweden’s representative in the EU’s High-Level Group on Health, and is a deputy board member of the WHO Collaborating Centre for International Drug Monitoring.
Cecilia has held several managerial and other senior positions within the Government Offices of Sweden, both at the Ministry of Health and Social Affairs and the Ministry for Foreign Affairs. She was a member of the Board and the Audit Committee of Systembolaget AB from 2017 to 2023. Cecilia also served as Secretary-General for the government inquiry that presented Sweden’s national cancer strategy.
Emma Lundberg, USA
Keynote Details
Speaker Details
KNL-03 | Tuesday, 15 September
11:45 - 12:30 - ESP Symeonidis Lecture
Title yet to be announced
Emma Lundberg is an academic scientist and an experienced leader of large interdisciplinary projects. Her expertise spans microscopy, cellular biology, artificial intelligence, citizen science, and games for health, with a strong passion for pioneering innovative solutions at their intersections. She serves as an advisor to companies ranging from biotech and AI startups to established biopharma organizations.
She is a strong advocate for open science and is known for fostering high-performance cultures that value open communication and prioritize creativity. Her goal is to leverage her interdisciplinary skills to build proteome-wide models of cells that can drive groundbreaking discoveries in biology and medicine.
Jason Hornick, USA
Keynote Details
Speaker Details
KNL-04 | Wednesday, 16 September
16:30 - 17:15 - Juan Rosai Lecture
Title yet to be announced
Jason Hornick is the Director of Surgical Pathology and Immunohistochemistry at Brigham and Women's Hospital, Professor of Pathology at Harvard Medical School, and a consultant at the Dana-Farber Cancer Institute.
He is a senior pathologist with expertise in soft tissue tumor pathology, gastrointestinal pathology, endocrine pathology, and diagnostic immunohistochemistry. Dr. Hornick was a member of the expert editorial board for the 4th (2013) and 5th (2020) editions of the World Health Organization (WHO) Classification of Tumors of Soft Tissue and Bone. He chaired the International Collaboration on Cancer Reporting (ICCR) dataset for gastrointestinal stromal tumors (GIST).
Dr. Hornick was a member of the Soft Tissue Sarcoma Expert Panel for the American Joint Committee on Cancer (AJCC) and the Sarcoma Analysis Working Group for The Cancer Genome Atlas (TCGA). He previously chaired the United States and Canadian Academy of Pathology (USCAP) Education Committee and the College of American Pathologists (CAP) Immunohistochemistry Committee and is currently on the USCAP Board of Directors.
Dr. Hornick serves on the Anatomic Pathology Test Development and Advisory Committee for the American Board of Pathology and the Council of the Arthur Purdy Stout Society of Surgical Pathologists. He is the Editor of the 5th series of the AFIP Atlases of Tumor and Non-tumor Pathology and Editor of the textbook Practical Soft Tissue Pathology: A Diagnostic Approach, which is in its 2nd edition. Dr. Hornick serves on 14 editorial boards, including the American Journal of Surgical Pathology and Modern Pathology. He is an Associate Editor for Sternberg’s Diagnostic Surgical Pathology, a Regional Editor for Histopathology, an Associate Editor for Advances in Anatomic Pathology and Virchows Archives, and the Consulting Editor for Surgical Pathology Clinics.
Dr. Hornick is dedicated to the advancement of diagnostic surgical pathology through improving tumor classification, defining histologic parameters that predict outcome, translating discoveries in basic biomedical research to clinical practice, and teaching approaches to diagnostic pathology to trainees and practitioners.